The following is a list of peer-reviewed journal articles pertaining to the microbiota-based products currently under development in the MRT™ drug platform. Click on the title to view complete information.
Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial
Robert Orenstein, Erik R. Dubberke, Sahil Khanna, Christine H. Lee, David Yoho, Stuart Johnson, Gail Hecht, Herbert L. DuPont, Dale N. Gerding, Ken F. Blount, Sarah Mische and Adam Harvey
Development and Validation of a Novel Microbiome-Based Biomarker of Post-antibiotic Dysbiosis and Subsequent Restoration
Ken Blount, Courtney Jones, Dana Walsh, Carlos Gonzalez and William D. Shannon
RBX7455, a Non-frozen, Orally Administered Investigational Live Biotherapeutic, Is Safe, Effective, and Shifts Patients’ Microbiomes in a Phase 1 Study for Recurrent Clostridioides difficile Infections
Sahil Khanna, Darrell S Pardi, Courtney Jones, William D Shannon, Carlos Gonzalez, Ken Blount
The effect of microbiota-based investigational drug RBX2660 on the gut microbiome and resistome revealed by a placebo-controlled clinical trial
Suryang Kwak, JooHee Choi, Tiffany Hink, Kimberly A. Reske, Kenneth Blount, Courtney Jones, Margaret H. Bost, Xiaoqing Sun, Carey-Ann D. Burnham, Erik R. Dubberke, Gautam Dantas
Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660—A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection
Erik R Dubberke, Christine H Lee, Robert Orenstein, Sahil Khanna, Gail Hecht, Dale N Gerding
Does the donor matter? Donor vs patient effects in the outcome of a next generation microbiota-based drug trial for recurrent Clostridium difficile infection
Arnab Ray and Courtney Jones
Restoration of Bacterial Microbiome Composition and Diversity Among Treatment Responders in a Phase 2 Trial of RBX2660: An Investigational Microbiome Restoration Therapeutic
Ken F. Blount, William D. Shannon, Elena Deych, and Courtney Jones
Clearance of Vancomycin-Resistant Enterococcus Concomitant With Administration of a Microbiota-based Drug Targeted at Recurrent Clostridium difficile Infection
Erik R. Dubberke, Kathleen M. Mullane, Dale N. Gerding, Christine H. Lee, Thomas J. Louie, Harriet Guthertz, and Courtney Jones
Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study
Robert Orenstein, Erik Dubberke, Robert Hardi, Arnab Ray, Kathleen Mullane, Darrell S. Pardi, and Mayur S. Ramesh; for the PUNCH CD Investigators
White Papers by Rebiotix
The following is a list of white papers by Rebiotix on subjects related to our industry and science. Click on the white paper title to view full details.
Published Summer 2016
Lee Jones, CEO, Rebiotix Inc.
Published June 2015